WHO Issues Concern Over Critical Scarcity of Weight-Loss Injections
Under one in 10 individuals that would benefit from obesity jabs including Wegovy are able to get them, states the global health agency as it publishes its initial recommendations on the drugs.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for more widespread and fairer availability to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"The latest guidance recognises that excess weight is a lifelong illness that can be treated with thorough and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant hurdles to universal access to the jabs that can assist patients in reducing substantial weight, notes the agency.
GLP-1 Therapy Scarcity
Despite the present best projected case, the production of such drugs would only suffice for about 100 million people – fewer than 10% of the global need, according to the health organization.
The recommendation calls on countries and companies to widen availability, by measures including patent sharing.
Exclusive production rights on a key compound – the main component of the drug Wegovy – is due to expire in a number of nations in 2026.
How Obesity Drugs Work
The injections replicate a natural hormone to delay gastric emptying, reduce hunger and boost the sense of being full so people reduce food intake.
People typically start to lose weight in the initial weeks of commencing the regular doses.
Studies indicates users may see weight return within a year of halting the drug, when their usual appetite return.
To be overweight or obese elevates your likelihood for experiencing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Obesity affects individuals in every country and was responsible for millions of fatalities worldwide in 2024, as per the health agency.
